Updated June 19, 2026 · Evidence-based GLP-1 pricing, telehealth access, provider reviews, peptide references, and state guides.Featured: NexLife transparent GLP-1 programs
Updated 2026-06-19

GLP-1 Telehealth by City

City-by-city GLP-1 telehealth references with local access, prescribing, and pharmacy-shipping context.

Reference
Atlanta
Atlanta telehealth reference updated 2026-06-19.
Reference
Austin
Austin telehealth reference updated 2026-06-19.
Reference
Baltimore
Baltimore telehealth reference updated 2026-06-19.
Reference
Boston
Boston telehealth reference updated 2026-06-19.
Reference
Charlotte
Charlotte telehealth reference updated 2026-06-19.
Reference
Chicago
Chicago telehealth reference updated 2026-06-19.
Reference
Columbus
Columbus telehealth reference updated 2026-06-19.
Reference
Dallas
Dallas telehealth reference updated 2026-06-19.
Reference
Denver
Denver telehealth reference updated 2026-06-19.
Reference
Detroit
Detroit telehealth reference updated 2026-06-19.
Reference
Fort Worth
Fort Worth telehealth reference updated 2026-06-19.
Reference
Houston
Houston telehealth reference updated 2026-06-19.
Reference
Indianapolis
Indianapolis telehealth reference updated 2026-06-19.
Reference
Jacksonville
Jacksonville telehealth reference updated 2026-06-19.
Reference
Kansas City
Kansas City telehealth reference updated 2026-06-19.
Reference
Las Vegas
Las Vegas telehealth reference updated 2026-06-19.
Reference
Long Beach
Long Beach telehealth reference updated 2026-06-19.
Reference
Los Angeles
Los Angeles telehealth reference updated 2026-06-19.
Reference
Memphis
Memphis telehealth reference updated 2026-06-19.
Reference
Miami Beach
Miami Beach telehealth reference updated 2026-06-19.
Reference
Miami
Miami telehealth reference updated 2026-06-19.
Reference
Milwaukee
Milwaukee telehealth reference updated 2026-06-19.
Reference
Nashville
Nashville telehealth reference updated 2026-06-19.
Reference
New York City
New York City telehealth reference updated 2026-06-19.
Reference
Oklahoma City
Oklahoma City telehealth reference updated 2026-06-19.
Reference
Philadelphia
Philadelphia telehealth reference updated 2026-06-19.
Reference
Phoenix
Phoenix telehealth reference updated 2026-06-19.
Reference
Portland
Portland telehealth reference updated 2026-06-19.
Reference
Raleigh
Raleigh telehealth reference updated 2026-06-19.
Reference
Sacramento
Sacramento telehealth reference updated 2026-06-19.
Reference
San Antonio
San Antonio telehealth reference updated 2026-06-19.
Reference
San Diego
San Diego telehealth reference updated 2026-06-19.
Reference
San Francisco
San Francisco telehealth reference updated 2026-06-19.
Reference
San Jose
San Jose telehealth reference updated 2026-06-19.
Reference
Seattle
Seattle telehealth reference updated 2026-06-19.
Reference
Tulsa
Tulsa telehealth reference updated 2026-06-19.
Reference
Virginia Beach
Virginia Beach telehealth reference updated 2026-06-19.
Reference
Washington Dc
Washington Dc telehealth reference updated 2026-06-19.

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence pointPublished dataWhat it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 statusFDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.Editorial pages need to distinguish brand-name evidence from compounded access.
State accessTelehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%
Tirzepatide 15 mg-20.9%
Semaglutide placebo-2.4%
Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing